Abstract:Objective: This study aimed to evaluate the diagnostic value of combining ultrasound-guided percutaneous biopsy with serum CA125 and CEA testing in ovarian tumors. Methods: Sixty-four patients suspected of having ovarian tumors, admitted to our hospital from July 2021 to July 2023, were selected for the study. All patients underwent ultrasound-guided percutaneous biopsy and serum tumor markers CA125 and CEA level testing. Surgical pathology results were used as the gold standard for comparison. The diagnostic performance of ultrasound-guided percutaneous biopsy alone, serum CA125, serum CEA, and their combination were evaluated. Receiver operating characteristic (ROC) curve analysis was performed, and the sensitivity, specificity, and accuracy were calculated. The differences in diagnostic performance were compared using the chi-square test, with a P < .05 considered statistically significant. Results: The results of this study demonstrate that combining ultrasound-guided percutaneous biopsy with serum CA125 and CEA testing significantly improved the diagnostic accuracy for ovarian tumors compared to individual testing modalities. Surgical pathology, the gold standard, confirmed 52 malignant and 12 benign tumors among the 64 patients examined. When evaluated individually, the concordance rate between ultrasound-guided biopsy and surgical pathology was 90.63%, while serum CA125 and CEA had diagnostic accuracies of 73.44% and 64.06%, respectively. However, when the two serum markers were used in combination, the diagnostic accuracy increased to 81.25%. Notably, the integration of ultrasound-guided percutaneous biopsy with serum CA125 and CEA testing produced the highest diagnostic accuracy at 95.31%. Statistical analysis confirmed this combined approach had significantly better accuracy, sensitivity, and specificity compared to individual tests (P < .05). ROC curve analysis further substantiated the superior diagnostic value of this integrated testing strategy. Conclusion: The findings of this study demonstrate that the integration of ultrasound-guided percutaneous biopsy with serum CA125 and CEA testing markedly enhances diagnostic accuracy for ovarian tumors, with a combined accuracy exceeding 95%. This integrated diagnostic protocol represents a robust and clinically valuable approach that should be more widely adopted to improve early detection and optimize the management of ovarian neoplasms. The implementation of this combined testing strategy has the potential to significantly impact clinical decision-making and patient outcomes in the diagnosis and treatment of ovarian tumors.

The Predictive Value of B Ultrasound and Serum CA_(125) for Ovarian Malignant Neoplasm in Postmenopausal Women

Clinical evaluation of serum CA-125 concentrations in ovary endometriosis patients

[Value of Serum CA(125) Detection for Predicting Recurrence and Prognosis in Ovarian Epithelial Cancer].

Preoperative predictive factor analysis of ovarian malignant involvement in premenopausal patients with clinical stage I endometrioid endometrial carcinoma

Evaluation of Serum CA125 in Diagnosis of Epithelial Ovarian Carcinoma

The Comparison of CA125 Alone and Multiterm Tumor Index Combined Detection in the Diagnosis of Ovarian Cancer

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer

Diagnostic Value of CA125,ultrasonography and Risk of Malignancy Index(rmi) in Postmenopausal Ovarian Masses

Clinical Significance of Combined Detection of HE4 and CA125 in the Serum and Tumor Tissues of Patients with Ovarian Cancer

Ultrasound-Guided Percutaneous Biopsy Combined Serum CA125, CEA Level Examination in the Diagnosis of Ovarian Tumors Value Analysis

Evaluation of Serum CA125-Tn Glycoform in Peritoneal Dissemination and Surgical Completeness of High-Grade Serous Ovarian Cancer

The Prognostic Value of the Serum CA125 Detection in Patients with Epithelial Ovarian Carcinoma

Prognostic Value Of Serum Ca19-9 And Perioperative Ca-125 Levels In Ovarian Clear Cell Carcinoma

Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis

Use of CA-125 and ultrasound in high-risk women

Does Combing O-RADS US and CA-125 Improve Diagnostic Accuracy in Assessing Adnexal Malignancy Risk in Women with Different Menopausal Status?

Evaluation of Serum Cancer Antigen (CA)-125 Levels as a Biomarker for Ovarian Lesions: Correlation With Histopathological Diagnosis and Clinical Outcomes

CA125 and Ovarian Cancer: A Comprehensive Review

A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis